Overview

OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Status:
Recruiting
Trial end date:
2026-04-04
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of oral OKI-179 combined with the MEK inhibitor binimetinib.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
OnKure, Inc.